Illumina, Inc. (NASDAQ:ILMN) Shares Acquired by Toroso Investments LLC

Toroso Investments LLC lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN – Get Rating) by 3.6% in the third quarter, Holdings Channel reports. The institutional investor owned 4,921 shares of the life sciences company’s stock after acquiring an additional 173 shares during the quarter. Toroso Investments LLC’s holdings in Illumina were worth $939,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in ILMN. Private Trust Co. NA purchased a new position in shares of Illumina during the 2nd quarter worth approximately $25,000. Zions Bancorporation N.A. boosted its position in shares of Illumina by 97.6% during the 3rd quarter. Zions Bancorporation N.A. now owns 164 shares of the life sciences company’s stock worth $31,000 after purchasing an additional 81 shares during the period. Guardian Wealth Advisors LLC purchased a new position in shares of Illumina during the 3rd quarter worth approximately $33,000. Massmutual Trust Co. FSB ADV boosted its position in shares of Illumina by 50.0% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 183 shares of the life sciences company’s stock worth $35,000 after purchasing an additional 61 shares during the period. Finally, SOA Wealth Advisors LLC. boosted its position in shares of Illumina by 282.7% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 199 shares of the life sciences company’s stock worth $37,000 after purchasing an additional 147 shares during the period. Institutional investors and hedge funds own 87.97% of the company’s stock.

Illumina Price Performance

ILMN stock opened at $224.55 on Friday. The stock has a market cap of $35.48 billion, a price-to-earnings ratio of -8.02, a PEG ratio of 8.32 and a beta of 1.15. Illumina, Inc. has a fifty-two week low of $173.45 and a fifty-two week high of $371.16. The business has a 50 day moving average price of $208.86 and a 200 day moving average price of $208.73. The company has a quick ratio of 1.08, a current ratio of 1.28 and a debt-to-equity ratio of 0.23.

Illumina (NASDAQ:ILMN – Get Rating) last released its quarterly earnings results on Tuesday, February 7th. The life sciences company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.11). The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a positive return on equity of 3.79% and a negative net margin of 96.12%. The company’s quarterly revenue was down 9.2% on a year-over-year basis. During the same period last year, the firm earned $0.75 EPS. Equities research analysts anticipate that Illumina, Inc. will post 1.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Piper Sandler reiterated an “overweight” rating and set a $290.00 target price on shares of Illumina in a report on Wednesday, February 8th. StockNews.com started coverage on Illumina in a report on Thursday. They set a “sell” rating on the stock. OTR Global upgraded Illumina from a “mixed” rating to a “positive” rating in a research note on Tuesday, December 20th. Barclays lowered their price objective on Illumina from $160.00 to $150.00 and set an “underweight” rating for the company in a research report on Wednesday, February 8th. Finally, Argus downgraded Illumina from a “buy” rating to a “hold” rating in a research report on Wednesday, January 25th. They noted that the move was a valuation call. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Illumina has a consensus rating of “Hold” and a consensus target price of $249.40.

Insiders Place Their Bets

In other Illumina news, SVP Aimee L. Hoyt sold 3,917 shares of Illumina stock in a transaction that occurred on Wednesday, March 1st. The stock was sold at an average price of $199.06, for a total transaction of $779,718.02. Following the transaction, the senior vice president now owns 2,881 shares of the company’s stock, valued at $573,491.86. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, SVP Alexander Aravanis sold 5,398 shares of the business’s stock in a transaction that occurred on Wednesday, February 22nd. The stock was sold at an average price of $201.74, for a total value of $1,088,992.52. Following the transaction, the senior vice president now owns 2,922 shares of the company’s stock, valued at $589,484.28. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Aimee L. Hoyt sold 3,917 shares of the company’s stock in a transaction that occurred on Wednesday, March 1st. The stock was sold at an average price of $199.06, for a total value of $779,718.02. Following the sale, the senior vice president now owns 2,881 shares of the company’s stock, valued at approximately $573,491.86. The disclosure for this sale can be found here. Insiders have sold a total of 11,186 shares of company stock valued at $2,255,837 over the last quarter. Company insiders own 0.13% of the company’s stock.

Illumina Company Profile

(Get Rating)

Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions.